The Impact of GLP Medication on Colonoscopy Bowel Preparation Quality
The Impact of GLP-1 Agonist and GIP Agonist on Bowel Preparation Quality: A Randomized Controlled Trial
The Cleveland Clinic
132 participants
Aug 1, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to learn how GLP-1 and GIP agonists effect bowel preparation in patients scheduled for colonoscopies. The main questions it aims to answer are: * Does GLP-1 and GIP agonist increase the rate of inadequate bowel preparation? * Does the quality of bowel preparation differ in patients who hold vs. those who continue a single dose of their GLP-1 or GIP agonist medication? * Are there any differences in the rates of complications gastric aspiration in patients who hold vs. continue a single dose of their GLP-1 or GIP agonist medication?
Eligibility
Inclusion Criteria3
- Adult patient (Age 18 years or older)
- Patient scheduled for outpatient screening, surveillance, or diagnostic colonoscopy
- Using a GLP-1 or GIP agonist at a stable dose for at least one month
Exclusion Criteria11
- Unable to provide informed consent, e.g., dementia
- Patient refuses the USMSTF recommended bowel cleansing regimen for patients with diabetes or obesity (split-dose 4 liters polyethylene glycol + 15 mg bisacodyl the afternoon before; low residue diet 3 days before colonoscopy; clear liquid diet the day before colonoscopy)
- Risk factors for inadequate bowel preparation besides diabetes and obesity with a likelihood ratio of 1.6 or greater:
- Cirrhosis
- Parkinson's disease
- Dementia
- Tricyclic antidepressant use
- Opioid use
- Gastroparesis* or suspected gastric outlet obstruction on pre-procedure imaging (*defined based on a documented 4-hour solid phase gastric emptying study or prior history of retained gastric contents during upper endoscopy)
- Previous colorectal surgery
- Prior history of inadequate bowel preparation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Continue GLP-1 or GIP-based therapy as prescribed prior to the procedure.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07127354